Clinical Trial Update: A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of ATG-010 with lenalidomide and rituximab in adults with diffuse large B-cell lymphoma and indolent non-Hodgkin lymphoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Indolent Non-hodgkin Lymphoma

Drugs mentioned

• ATG-010
• Lenalidomide (lenalidomide)
• Rituximab (rituximab)

Snippet

Sponsor: Antengene Corporation | Conditions: Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: TERMINATED